Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:FBRX NASDAQ:FULC NASDAQ:SCLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$2.60-0.8%$2.93$2.41▼$13.99$240.95M1.21.41 million shs794,894 shsFBRXForte Biosciences$21.32+1.4%$22.35$9.10▼$35.80$296.14M2.87284,877 shs473,387 shsFULCFulcrum Therapeutics$3.73-1.8%$5.74$2.83▼$15.74$248.53M2.931.64 million shs1.52 million shsSCLXScilex$7.80+9.7%$7.27$4.20▼$34.27$66.22M1.771,437 shs48,294 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences0.00%-4.03%-13.53%-7.09%-72.36%FBRXForte Biosciences0.00%+17.82%+10.28%-20.10%+71.67%FULCFulcrum Therapeutics0.00%+2.70%-45.09%-42.25%-46.48%SCLXScilex0.00%-4.82%-20.11%+12.32%+17.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$2.60-0.8%$2.93$2.41▼$13.99$240.95M1.21.41 million shs794,894 shsFBRXForte Biosciences$21.32+1.4%$22.35$9.10▼$35.80$296.14M2.87284,877 shs473,387 shsFULCFulcrum Therapeutics$3.73-1.8%$5.74$2.83▼$15.74$248.53M2.931.64 million shs1.52 million shsSCLXScilex$7.80+9.7%$7.27$4.20▼$34.27$66.22M1.771,437 shs48,294 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences0.00%-4.03%-13.53%-7.09%-72.36%FBRXForte Biosciences0.00%+17.82%+10.28%-20.10%+71.67%FULCFulcrum Therapeutics0.00%+2.70%-45.09%-42.25%-46.48%SCLXScilex0.00%-4.82%-20.11%+12.32%+17.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 2.40Hold$21.33720.51% UpsideFBRXForte Biosciences 2.50Moderate Buy$67.00214.26% UpsideFULCFulcrum Therapeutics 1.75Reduce$8.20119.84% UpsideSCLXScilex 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SCLX, AVXL, FBRX, and FULC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026SCLXScilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/11/2026AVXLAnavex Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026FULCFulcrum Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight6/2/2026FULCFulcrum Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeUnderperform ➝ Underweight6/2/2026FULCFulcrum Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.006/2/2026FULCFulcrum Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$4.006/2/2026FULCFulcrum Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$3.006/2/2026FULCFulcrum Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/2/2026FULCFulcrum Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$4.006/2/2026FULCFulcrum Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$3.006/2/2026FULCFulcrum Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.00(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.10 per shareN/AFBRXForte BiosciencesN/AN/AN/AN/A$4.71 per shareN/AFULCFulcrum Therapeutics$80M3.11N/AN/A$6.45 per share0.58SCLXScilex$30.25M2.19N/AN/A($24.94) per share-0.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$46.38M-$0.46N/AN/AN/AN/A-38.76%-35.01%6/30/2026 (Estimated)FBRXForte Biosciences-$69.38M-$4.64N/AN/AN/AN/A-106.17%-85.50%8/13/2026 (Estimated)FULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%8/4/2026 (Estimated)SCLXScilex-$358.73M-$40.47N/AN/AN/A-1,110.17%N/A-143.55%9/2/2026 (Estimated)Latest SCLX, AVXL, FBRX, and FULC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/30/2026Q2 2026AVXLAnavex Life Sciences-$0.07-$0.07N/AN/AN/AN/A5/20/2026Q1 2026SCLXScilex-$0.3373-$4.76-$4.4227-$6.28$15.00 million$8.61 million5/11/2026Q1 2026FBRXForte Biosciences-$1.16-$1.24-$0.08-$1.24N/AN/A4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/A4/10/2026Q4 2025SCLXScilex-$0.47-$4.60-$4.13-$4.60$12.10 million$4.79 million3/31/2026Q4 2025FBRXForte Biosciences-$1.42-$1.45-$0.03-$1.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/ASCLXScilexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A20.8720.87FBRXForte BiosciencesN/A2.752.75FULCFulcrum TherapeuticsN/A34.3334.33SCLXScilexN/A0.080.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%FBRXForte Biosciences77.63%FULCFulcrum Therapeutics89.83%SCLXScilex69.67%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%FBRXForte Biosciences4.40%FULCFulcrum Therapeutics7.30%SCLXScilex4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4092.67 million82.48 millionOptionableFBRXForte Biosciences513.89 million13.28 millionOptionableFULCFulcrum Therapeutics10066.63 million61.77 millionOptionableSCLXScilex808.49 million8.11 millionNo DataSCLX, AVXL, FBRX, and FULC HeadlinesRecent News About These CompaniesScilex Stockholders Approve Director Election and Equity PlanJune 24, 2026 | tipranks.comScilex (NASDAQ:SCLX) Shares Up 18% - Here's What HappenedJune 18, 2026 | americanbankingnews.comScilex Holding Company to List Dream Bowl Tokens on Biconomy Exchange Starting June 23, 2026June 16, 2026 | quiverquant.comQScilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026June 16, 2026 | globenewswire.comScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders ...June 12, 2026 | finance.yahoo.comScilex Holding Company Announces Dividend Payment Date for Semnur Pharmaceuticals Common StockJune 12, 2026 | quiverquant.comQScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesJune 12, 2026 | globenewswire.comScilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...June 5, 2026 | theglobeandmail.comScilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...June 4, 2026 | markets.businessinsider.comScilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity SecuritiesJune 4, 2026 | globenewswire.comScilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other ...May 22, 2026 | markets.businessinsider.comScilex Holding Company Declares Dividend of Semnur Pharmaceuticals Common Stock to ShareholdersMay 22, 2026 | quiverquant.comQScilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026May 22, 2026 | globenewswire.comScilex Delays Quarterly Report Amid Consolidation WorkMay 15, 2026 | tipranks.comScilex Announces Special Dream Bowl Token DividendMay 11, 2026 | tipranks.comPHOE stock more than doubles on strategic pivot into pharma industry with Scilex dealMay 5, 2026 | msn.comScilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings LimitedMay 5, 2026 | theglobeandmail.comScilex Subsidiary Reshapes Phoenix Asia via $1B Share DealMay 5, 2026 | tipranks.comScilex Holding Company Announces Acquisition Agreement Between ACEA Therapeutics and Phoenix Asia HoldingsMay 5, 2026 | quiverquant.comQScilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to ...May 4, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSCLX, AVXL, FBRX, and FULC Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$2.60 -0.02 (-0.76%) Closing price 04:00 PM EasternExtended Trading$2.51 -0.09 (-3.58%) As of 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Forte Biosciences NASDAQ:FBRX$21.32 +0.29 (+1.38%) Closing price 04:00 PM EasternExtended Trading$21.31 -0.01 (-0.05%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Fulcrum Therapeutics NASDAQ:FULC$3.73 -0.07 (-1.84%) Closing price 04:00 PM EasternExtended Trading$3.74 +0.00 (+0.13%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Scilex NASDAQ:SCLX$7.80 +0.69 (+9.70%) Closing price 04:00 PM EasternExtended Trading$7.90 +0.09 (+1.22%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
